The therapeutic index of very toxic, oxidative drugs could be improved by concurrent treatment with other agents, such as methylene blue, which affect the concn of intracellular reducing agents. In support of this hypothesis, methylene blue was found to protect mice against the toxic effects of doxorubicin without reducing doxorubicin's antineoplastic activity.